The company clocked a sales growth of 11.8 percent in 2017 on the back of increased volumes, especially in Maggi.
Margins are being sacrificed to secure future growth, said PhillipCapital.
Tata Motors is the worst performer on the Nifty Auto Index in the last one year.
What to expect from India Inc.’s earnings season that kicks off on April 13.
The observations stem from last month’s surprise inspection conducted from March 19-27.
Shares of Fortis Healthcare fell the most in a month amid concerns about its valuation.
Consensus target price of analysts suggest potential upside of 25 percent for Jubilant Life.
Analysts are betting on a Cadila Healthcare Ltd. turnaround.
This in an important milestone for Sun Pharma as its generic launches face pricing pressure in its key market.
The U. S. Food and Drug Administration officials began inspecting the site yesterday.
Equity benchmarks across Asia and Europe have given negative returns since January 29, led by Nikkei 225.
Cipla received eight observations regarding manufacturing practices at its Goa plant.
Domestic pharmaceutical stocks lose sheen, but global peers in the Indian market continue to shine.
The U.S. FDA’s observations for Sun Pharma’s Halol plant show that it may soon get the green signal.
FDA’s observations are procedural and don’t point to any data integrity issues.
Majority of the U.S. FDA’s observations For Aurobindo Pharma’s Unit 4 are relating to equipment and cleanliness.
Siemens sells mobility, mechanical drives divisions to parent as part of global rejig.
Sun Pharma’s near-term fortunes are tied to the outcome of U.S. FDA’s inspection of its Halol plant.
Here’s why brokerages are still bullish on Fortis despite the founder troubles.
Half of the Nifty50 stocks reported earnings that were in-line with analyst expectations.
The inspection was done due to multiple recall of product recall of a drug in 2017 and issues of stability failure.